Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sagimet Biosciences Inc. filings document a clinical-stage biopharmaceutical issuer with Series A common stock listed on the Nasdaq Global Market and emerging growth company status. Recent 8-K reports cover financial results, preliminary financial information, Regulation FD investor presentations, a material underwriting agreement and related capital-structure disclosures, and executive leadership changes.
The company’s proxy materials describe annual meeting voting matters, stockholder procedures, board-related items, and governance proposals. Its disclosures also track use-of-proceeds language, clinical-development updates for FASN inhibitor programs, and public-company reporting matters.
Sagimet Biosciences Inc. reported new long-term equity awards for three senior officers. On May 28, 2026, the company granted stock options and performance-based restricted stock units (PSUs) under its 2023 Stock Option and Incentive Plan to its CEO, CFO, and Chief Legal and Administrative Officer.
CEO David Happel received 300,000 options and 300,000 PSUs, CFO Thierry Chauche received 50,000 options and 50,000 PSUs, and Chief Legal and Administrative Officer Elizabeth Rozek received 100,000 options and 100,000 PSUs. Each option has an exercise price of $7.27 per share, matching the Series A common stock closing price on the grant date, and vests in equal installments over 48 months.
The PSUs will be earned based on the company’s achievement of specified regulatory milestones. For each officer, one-third of the earned PSUs will vest on the date the Compensation Committee determines that these milestones were achieved, with the remaining two-thirds vesting in two equal installments on the first and second anniversaries of that determination date.
Sagimet Biosciences granted its Chief Financial Officer, Thierry Chauche, a stock option to acquire 50,000 shares of Series A Common Stock. The option has a $7.27 per-share exercise price and expires on May 27, 2036.
According to the filing, these options vest in 48 equal monthly installments beginning after May 28, 2026, contingent on his continued service. Following this grant, Chauche holds 50,000 stock options directly, reflecting routine equity-based compensation rather than an open-market transaction.
Sagimet Biosciences Inc. reported that Chief Medical Officer Andreas Grauer received a grant of stock options. The grant covers 35,000 Stock Options (Right to Buy), each exercisable for one share of Series A Common Stock at an exercise price of $7.27 per share.
The options vest in forty-eight equal monthly installments starting on May 28, 2026, conditioned on Dr. Grauer’s continued service on each vesting date. Following this grant, the filing shows Dr. Grauer directly holding 35,000 options under this award.
Sagimet Biosciences Inc. reported that Chief Legal & Admin. Officer Elizabeth Rozek received a grant of stock options as part of her compensation. She was awarded 100,000 stock options, each giving the right to buy one share of Series A common stock at an exercise price of $7.27 per share. These options expire on May 27, 2036. According to the terms, the shares underlying this option will vest in 48 equal monthly installments beginning after May 28, 2026, contingent on her continued service, and her reported derivative holdings after this grant total 100,000 options.
Sagimet Biosciences Inc. reported that President & CEO David Happel received a grant of stock options covering 300,000 shares of Series A common stock. The options have an exercise price of $7.27 per share and were awarded at no cost to him.
These options vest in forty-eight equal monthly installments starting on May 28, 2026, contingent on his continued service. After this grant, he holds options on 300,000 shares according to the filing. The transaction reflects equity-based compensation rather than an open-market purchase or sale.
Sagimet Biosciences reported that Chief Medical Officer Andreas Grauer received a grant of stock options covering 264,759 shares of Series A common stock. The options have an exercise price of $6.44 per share and expire on April 19, 2036.
According to the vesting terms, 25% of the underlying shares vest on April 20, 2027, with the remaining 75% vesting in 36 equal monthly installments, contingent on continued service. Following this grant, Grauer holds derivative rights over 264,759 shares through this option award.
Sagimet Biosciences Inc. filed a Form 3 insider report for Andreas Grauer, who is identified as the company’s Chief Medical Officer. The filing does not list any securities transactions or derivative positions, and no share holdings are detailed in the provided data.
Sagimet Biosciences reported first quarter 2026 results alongside major financing and pipeline updates. The company completed a $175 million equity financing in April 2026 and now expects its cash, cash equivalents and marketable securities to fund operations through 2028, including data readout from a planned Phase 3 acne trial of denifanstat.
For the quarter ended March 31, 2026, Sagimet reported a net loss of $10.7 million compared with $18.2 million a year earlier, as total operating expenses fell to $11.7 million from $19.9 million. Net loss per share improved to $0.33 from $0.56, with weighted-average shares of about 32.6 million. Cash, cash equivalents and marketable securities were $104.5 million as of March 31, 2026, down modestly from $113.1 million at year-end 2025.
Sagimet Biosciences Inc. reported a net loss of $10.7 million for the quarter ended March 31, 2026, an improvement from $18.2 million a year earlier. The smaller loss was driven by a 54% drop in research and development expense to $7.0 million as Phase 3 MASH work wound down and spending shifted toward acne programs.
General and administrative costs were stable at $4.7 million, while other income declined to $1.1 million due to lower cash balances and yields. Sagimet ended the quarter with $104.5 million in cash, cash equivalents and marketable securities and then raised about $175.0 million in an April 2026 underwritten offering, which it expects to fund operations for at least 12 months.
The company continues to advance FASN inhibitor programs: denifanstat, which met Phase 3 acne endpoints in China through its partner Ascletis, is planned to enter a U.S. Phase 3 acne trial after an IND filing in mid-2026, and TVB-3567 is in a Phase 1 acne study. Further MASH development will pause until non-dilutive financing is secured.
Sagimet Biosciences Inc. entered into an underwriting agreement for an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share. The Company expects to receive $164.5 million in net proceeds after underwriting discounts and commissions.
The Company plans to use the proceeds, together with existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, advance TVB-3567 through Phase 2 topline results, move a topical FASN inhibitor to IND submission, and for general corporate purposes including additional clinical development, working capital and operating expenses.